Janux Therapeutics (JANX) Stock Forecast & Price Target

Janux Therapeutics is viewed positively because its tumor-activated masking platforms, especially TRACTr and TRACIr, appear capable of improving the therapeutic window of T cell engagers by restricting activity to tumors while preserving efficacy, with JANX007 already showing robust clinical activity in mCRPC. The key fundamental catalyst is the 1H27 JANX007 update in taxane-naive mCRPC, where ongoing dose optimization and the darolutamide cohort could show durability and manageable CRS versus the high bar set by Pluvicto’s ~11.5-12m rPFS, potentially de-risking a pivotal path. The company is also well capitalized with $971m in cash at 2Q26, while JANX013 and JANX014 broaden pipeline optionality and JANX011 adds autoimmune upside, supporting a rerating case.

Janux Therapeutics is a clinical-stage biopharmaceutical company with an inherently high-risk profile, as its valuation depends on unproven tumor-activated immunotherapy platforms and the success of JANX007, which could disappoint on efficacy or safety. Its outlook is further weakened by the possibility of unforeseen delays in R&D, regulatory, or commercial development, alongside intense competition in the mCRPC space and meaningful clinical, regulatory, and supply chain risks. Liquidity and financing concerns also matter, because an inability to raise sufficient capital for research could impede development across its TRACTr, TRACIr, and ARM programs.